Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: A paradoxical effect?

Journal of Rheumatology

Volumn 38, Issue 10, 2011, Pages 2284-

  Wendling, Daniel ^a   Dernis, Emmanuelle ^b   Prati, Clément ^a   Frisch, Eric ^c   Delbosc, Bernard ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b General Hospital of le Mans   (France)

^c Private Office in Ophthalmology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; EYE DROPS; HLA B27 ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISONE; RHEUMATOID FACTOR; STEROID; TOCILIZUMAB;

ADULT; AGED; ANKYLOSING SPONDYLITIS; CASE REPORT; DISEASE ACTIVITY; DISEASE DURATION; DRUG RESPONSE; DRUG WITHDRAWAL; EOSINOPHILIA; EYE DISEASE; EYE INFLAMMATION; HUMAN; INFLAMMATORY DISEASE; IRIDOCYCLITIS; KERATITIS; LETTER; MALE; PRIORITY JOURNAL; RELAPSE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; ULCERATIVE KERATITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EYE DISEASES; HUMANS; INFLAMMATION; MALE; RECEPTORS, INTERLEUKIN-6;

EID: 80053470017     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110170     Document Type: Letter

References (10)

1. Pham T, Claudepierre P, Constantin A, De Bandt M, Fautrel B, Gossec L, et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010;77 Suppl 1:S3-100.
2. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
3. Wendling D, Paccou J, Flipo RM, Dernis E, Direz G, Ferrazzi V, et al. New onset of uveitis under anti TNF therapy. A nationwide series [abstract]. Arthritis Rheum 2010;62 Suppl:S374-375.
4. Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Orcel P, Lioté F. A new paradoxical effect of etanercept? A series of 3 cases and systematic literature review of etanercept-associated inflammatory eye disease [abstract]. Arthritis Rheum 2010;62 Suppl:S174.
5. Kramer M, Monselise Y, Bahar I, Cohen Y, Weinberger D, Goldenberg-Cohen N. Serum cytokine levels in active uveitis and remission. Curr Eye Res 2007;32:669-75. (Pubitemid 47400689)
6. Xu Y, Chen W, Lu H, Hu X, Li S, Wang J, et al. The expression of cytokines in the aqueous humor and serum during endotoxin-induced uveitis in C3H/HeN mice. Mol Vis 2010;16:1689-95.
7. Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 2010;91:162-70.
8. Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology 2009;48:347-54.
9. Simon D, Denniston AK, Tomlins PJ, Wallace GR, Rauz S, Salmon M, et al. Soluble gp130, an antagonist of IL-6 transsignaling, is elevated in uveitis aqueous humor. Invest Ophthalmol Vis Sci 2008;49:3988-91.
10. Hume EB, Cole N, Garthwaite LL, Khan S, Willcox MD. A protective role for IL-6 in staphylococcal microbial keratitis. Invest Ophthalmol Vis Sci 2006;47:4926-30. (Pubitemid 46586394)